Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
about
Role of oxidative stress and antioxidants in neurodegenerative diseases.Neurobiological characterization of bipolar affective disorders : a focus on tardive dyskinesia and soft neurological signs in relation to serum dopamine Beta hydroxylase activity.Parkinsonism treatment: Part III--Update.The development of mitochondrial medicine.Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl.Antioxidative therapeutic strategies for Parkinson's disease.Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United KingdomMonoamine oxidase-B inhibition in the treatment of Parkinson's disease.Pharmacological approaches to disease-modifying therapies in Parkinson's disease.The modern management of Parkinson's disease.Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.Toxic effects of Mn2O3 nanoparticles on rat testis and sex hormone.The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.Drug treatment of Parkinson's disease.Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea pig striatum.Evidence of oxidative stress in young and aged DJ-1-deficient mice.Protective effect of N-(2-propynyl)-2-(5-benzyloxyindolyl) methylamine (PF 9601N), a novel MAO-B inhibitor, on dopamine-lesioned PC12 cultured cells.Current status of antioxidant therapy for Alzheimer's Disease.Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.
P2860
Q34154938-338B3453-751B-4C0F-83D6-44FE6B132940Q34253507-EA10A6CA-09E4-4971-AB35-E03294164119Q35252285-0C211C5F-F27B-49F1-8F07-049B2EC4B9CCQ35744478-DF9C1F3B-7011-43F0-A768-36F7D1E84523Q35873611-E0325696-3581-4AE8-AE06-C4F97C25F847Q36349448-A2A6370C-40F2-4E21-BEEE-142A97419E36Q36790493-E71041A7-08D8-4F41-BC4A-A6EB35448A85Q37016034-32EFD815-3879-4748-AEAB-53D041D914F4Q37610212-B1364D2D-B32C-4274-B7C1-3E852F3F936CQ37809006-FD98D3CC-F8E0-4CEA-BD85-F90BD50CD2FCQ39084564-0343FF05-112B-4603-BC87-9139B4475D24Q41927560-996ACBB3-5D9B-4E95-AC5D-D909DFA40A33Q42402814-706A8170-9456-4359-8CFB-010A4CFD1107Q42531912-E5A42AEB-3AAE-4663-A109-6EE56D110EC2Q42725618-BB7E4668-8260-43AC-B1C2-6BEE3EE41A2DQ44112135-3C92FF1C-868D-4B76-A748-FF0B8F09B4C4Q44157297-6DC46D8F-6263-40FB-A38E-0CEDB363A95EQ44435362-80A6A244-D957-4780-86AE-66BA43EDA24FQ44494634-12C6ABF7-FD2E-4908-965C-9F1761F6B57EQ48331742-CEF91DDD-E230-49D4-AEAD-7FEBBCC1CBA6Q53726927-81BBA3CE-E2F7-4A07-B4E7-B27870C38506
P2860
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@en
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@nl
type
label
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@en
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@nl
prefLabel
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@en
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@nl
P356
P1433
P1476
Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
@en
P2093
P304
P356
10.1002/ANA.410260518
P577
1989-11-01T00:00:00Z